Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders (RIC)

  • End date
    Dec 8, 2024
  • participants needed
  • sponsor
    Children's Hospital of Philadelphia
Updated on 8 April 2022
mycophenolate mofetil
transplant conditioning
shortening fraction
reduced intensity conditioning
bone marrow failure
wiskott-aldrich syndrome
severe combined immunodeficiency


This is a Phase II pilot study to evaluate engraftment and toxicity of patients with non-malignant diseases using a reduced intensity conditioning regimen in the setting of allogeneic transplant for non malignant diseases. Bone Marrow or cord blood will be acceptable as a stem cell source.

Recently, reduced intensity conditioning (RIC) regimens have been used for both adult patients with leukemias and pediatric patients with non-malignant diseases. These regimens are better tolerated, resulting in less transplant related morbidity and mortality. Stable mixed chimerism, while insufficient for eradication of leukemias, may be sufficient to cure patients with non-malignant diseases.


There are two conditioning regimens in this protocol for children >6 months. Alemtuzumab (Campath), Fludarabine and Melphalan are used. The regimens differ by the timing and dosing of Alemtuzumab (Campath). The two timings are distal and intermediate.

  • Distal campath is initiated 22 days prior to the allogeneic transplant.
  • Intermediate campath is initiated 14 days prior to allogeneic transplant.

The conditioning regimen for children with immunodeficiencies <6 months omits melphalan, and substitutes two days of busulfan. This regimen is successfully used in the United Kingdom, and has been successful in a 3 month old infant at the Children's Hospital of Philadelphia (CHOP) who engrafted with a haploidentical donor.

Condition Non Malignant Diseases, Immunodeficiencies, Hemoglobinopathies
Treatment RIC: Distal Campath, RIC:Intermediate Campath, RIC: Mini Busulfan
Clinical Study IdentifierNCT01050855
SponsorChildren's Hospital of Philadelphia
Last Modified on8 April 2022


Yes No Not Sure

Inclusion Criteria

Age >6 months- 25 years
Diseases eligible for Distal Alemtuzumab
Immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome
Sickle cell disease
Thalassemia major
Bone marrow failure
Diseases eligible for Intermediate Alemtuzumab
Hemophagocytic lymphohistiocytosis other macrophage activation syndromes, severe Langerhans histiocytosis
Severe combined immune deficiency, adenosine deaminase deficiency, common variable immunodeficiency
Wiskott-Aldrich syndrome
Organ criteria
Cardiac: Echocardiogram shortening fraction >27%
Renal: Serum creatinine less than 1.5 times the upper limit of normal for age
Hepatic: liver function tests must be less than 5 times the upper limit of normal
No active infections

Exclusion Criteria

Uncontrolled bacterial, fungal or viral infections
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note